{"groups":[{"description":"Phase I Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"FG000","title":"1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"FG001","title":"1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"FG002","title":"1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"FG003","title":"1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide"},{"description":"Phase I Twice Weekly 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"FG004","title":"Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"FG005","title":"Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"FG006","title":"Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham"},{"description":"Phase I Twice Weekly 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"FG007","title":"Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide; Pegylated G-CSF","id":"FG008","title":"Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami"},{"description":"Phase II Randomized Weekly bortezomib dosing schedule","id":"FG009","title":"Weekly Bortezomib Dosing Schedule"},{"description":"Phase II Randomized Twice-weekly bortezomib dosing schedule","id":"FG010","title":"Twice-weekly Bortezomib Dosing Schedule"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"}],"type":"Not Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"10"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"10"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}